HLA class II polymorphisms as prognostic biomarkers for right and left-sided colon cancer.

IF 2.3 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

International Journal of Biological Markers Pub Date : 2024-03-01 Epub Date: 2024-01-05 DOI:10.1177/03936155231224469

Amani Attia, Awatef Lagha, Amel Mezlini, Ezzedine Ghazouani, Besma Yacoubi-Loueslati, Imene Namouchi

{"title":"HLA class II polymorphisms as prognostic biomarkers for right and left-sided colon cancer.","authors":"Amani Attia, Awatef Lagha, Amel Mezlini, Ezzedine Ghazouani, Besma Yacoubi-Loueslati, Imene Namouchi","doi":"10.1177/03936155231224469","DOIUrl":null,"url":null,"abstract":"Background: Colon cancer (CC) is one of the most common malignancies worldwide. Characterization of new prognostic biomarkers for right-sided CC (RCC) and left-sided CC (LCC) may contribute to improving early detection. An association of human leukocyte antigens class II (HLA-II) with the predisposition to CC was suggested.Aim of the study: We evaluated the association of DRB1 and DQB1 with the risk of LCC and RCC.Patients and methods: Our study comprised 93 CC patients and 100 healthy controls. Genotyping of HLA class II alleles were performed by the Polymerase Chain Reaction Sequence-Specific Primers (PCR-SSP).Results: DRB1*03 was positively associated with CC. In contrast, DRB1*11, DRB1*13, DQB1*03, and DQB1*05 were negatively linked to CC. Haplotype analysis revealed that DRB1*04-DQB1*04 and DRB1*09-DQB1*02 were positive, while DRB1*01-DQB1*05, DRB1*04-DQB1*03, DRB1*07-DQB1*02, DRB1*11-DQB1*03, DRB1*11-DQB1*05, and DRB1*13-DQB1*06 were negatively associated with CC. For sigmoid CC, DRB1*13, DRB1*11, and DQB1*05 were negative, while DRB1*04-DQB1*02, and DRB1*07-DQB1*03 were positively associated. DRB1*03 and DRB1*04-DQB1*04 were positive, while DRB1*11 and DQB1*03 were negatively linked to RCC. According to the LCC, DRB1*07, DRB1*11, DQB1*03, DQB1*05, and DRB1*07-DQB1*02 were negative. In contrast, DRB1*09-DQB1*02 was positively associated with LCC. Stratified analysis revealed that DRB1*11 is associated with higher risk of metastasis in CC and sigmoid CC, and tolerance to treatment in RCC. DQB1*03 was associated with lymph-node invasion in CC.Conclusion: DRB1 and DQB1 polymorphisms could be used as future biomarkers for the early detection of subjects at a higher risk of developing RCC and LCC, metastasis in sigmoid CC, and tolerance to treatment in RCC.","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"40-51"},"PeriodicalIF":2.3000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155231224469","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Colon cancer (CC) is one of the most common malignancies worldwide. Characterization of new prognostic biomarkers for right-sided CC (RCC) and left-sided CC (LCC) may contribute to improving early detection. An association of human leukocyte antigens class II (HLA-II) with the predisposition to CC was suggested.

Aim of the study: We evaluated the association of DRB1 and DQB1 with the risk of LCC and RCC.

Patients and methods: Our study comprised 93 CC patients and 100 healthy controls. Genotyping of HLA class II alleles were performed by the Polymerase Chain Reaction Sequence-Specific Primers (PCR-SSP).

Results: DRB1*03 was positively associated with CC. In contrast, DRB1*11, DRB1*13, DQB1*03, and DQB1*05 were negatively linked to CC. Haplotype analysis revealed that DRB1*04-DQB1*04 and DRB1*09-DQB1*02 were positive, while DRB1*01-DQB1*05, DRB1*04-DQB1*03, DRB1*07-DQB1*02, DRB1*11-DQB1*03, DRB1*11-DQB1*05, and DRB1*13-DQB1*06 were negatively associated with CC. For sigmoid CC, DRB1*13, DRB1*11, and DQB1*05 were negative, while DRB1*04-DQB1*02, and DRB1*07-DQB1*03 were positively associated. DRB1*03 and DRB1*04-DQB1*04 were positive, while DRB1*11 and DQB1*03 were negatively linked to RCC. According to the LCC, DRB1*07, DRB1*11, DQB1*03, DQB1*05, and DRB1*07-DQB1*02 were negative. In contrast, DRB1*09-DQB1*02 was positively associated with LCC. Stratified analysis revealed that DRB1*11 is associated with higher risk of metastasis in CC and sigmoid CC, and tolerance to treatment in RCC. DQB1*03 was associated with lymph-node invasion in CC.

Conclusion: DRB1 and DQB1 polymorphisms could be used as future biomarkers for the early detection of subjects at a higher risk of developing RCC and LCC, metastasis in sigmoid CC, and tolerance to treatment in RCC.

查看原文本刊更多论文

作为左右侧结肠癌预后生物标志物的 HLA II 类多态性。

背景：结肠癌（CC）是全球最常见的恶性肿瘤之一：结肠癌（CC）是全球最常见的恶性肿瘤之一。确定右侧结肠癌（RCC）和左侧结肠癌（LCC）的新预后生物标志物可能有助于提高早期发现率。研究表明，人类白细胞抗原II类（HLA-II）与CC的易感性有关：研究目的：我们评估了 DRB1 和 DQB1 与 LCC 和 RCC 风险的关系：我们的研究包括 93 名 CC 患者和 100 名健康对照者。采用聚合酶链式反应序列特异性引物（PCR-SSP）对 HLA II 类等位基因进行基因分型：结果：DRB1*03与CC呈正相关。结果：DRB1*03 与 CC 呈正相关，而 DRB1*11、DRB1*13、DQB1*03 和 DQB1*05 与 CC 呈负相关。单倍型分析表明，DRB1*04-DQB1*04 和 DRB1*09-DQB1*02 与 CC 呈正相关，而 DRB1*01-DQB1*05、DRB1*04-DQB1*03、DRB1*07-DQB1*02、DRB1*11-DQB1*03、DRB1*11-DQB1*05 和 DRB1*13-DQB1*06 与 CC 呈负相关。对于乙状结肠 CC，DRB1*13、DRB1*11 和 DQB1*05 呈负相关，而 DRB1*04-DQB1*02 和 DRB1*07-DQB1*03 呈正相关。DRB1*03 和 DRB1*04-DQB1*04 与 RCC 呈正相关，而 DRB1*11 和 DQB1*03 与 RCC 呈负相关。根据 LCC，DRB1*07、DRB1*11、DQB1*03、DQB1*05 和 DRB1*07-DQB1*02 呈阴性。相比之下，DRB1*09-DQB1*02 与 LCC 呈正相关。分层分析显示，DRB1*11与CC和乙状结肠CC的较高转移风险以及RCC的治疗耐受性相关。DQB1*03与CC的淋巴结侵犯有关：结论：DRB1和DQB1多态性可作为未来的生物标记物，用于早期检测RCC和LCC的高风险人群、乙状结肠CC的转移以及RCC的治疗耐受性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Biological Markers 医学-生物工程与应用微生物

CiteScore

4.10

自引率

0.00%

发文量

期刊介绍： IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.